Literature DB >> 17392506

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

Monica V Goldberg1, Charles H Maris, Edward L Hipkiss, Andrew S Flies, Lijie Zhen, Rubin M Tuder, Joseph F Grosso, Timothy J Harris, Derese Getnet, Katharine A Whartenby, Dirk G Brockstedt, Thomas W Dubensky, Lieping Chen, Drew M Pardoll, Charles G Drake.   

Abstract

Expression of the PD-1 receptor on T cells has been shown to provide an important inhibitory signal that down-modulates peripheral effector responses in normal tissues and tumors. Furthermore, PD-1 up-regulation on chronically activated T cells can maintain them in a partially reversible inactive state. The function of PD-1 in the very early stages of T-cell response to antigen in vivo has not been fully explored. In this study, we evaluate the role of PD-1 and its 2 B7 family ligands, B7-H1 (PD-L1) and B7-DC (PD-L2), in early fate decisions of CD8 T cells. We show that CD8 T cells specific for influenza hemagglutinin (HA) expressed as a self-antigen become functionally tolerized and express high levels of surface PD-1 by the time of their first cell division. Blockade of PD-1 or B7-H1, but not B7-DC, at the time of self-antigen encounter mitigates tolerance induction and results in CD8 T-cell differentiation into functional cytolytic T lymphocytes (CTLs). These findings demonstrate that, in addition to modulating effector functions in the periphery, B7-H1:PD-1 interactions regulate early T-cell-fate decisions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392506      PMCID: PMC1896112          DOI: 10.1182/blood-2006-12-062422

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  The B7 family revisited.

Authors:  Rebecca J Greenwald; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 2.  Peripheral tolerance of CD8 T lymphocytes.

Authors:  William L Redmond; Linda A Sherman
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

3.  Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.

Authors:  Hans Christian Probst; Kathy McCoy; Taku Okazaki; Tasuku Honjo; Maries van den Broek
Journal:  Nat Immunol       Date:  2005-01-30       Impact factor: 25.606

Review 4.  The emerging role of CTLA-4 as an immune attenuator.

Authors:  C B Thompson; J P Allison
Journal:  Immunity       Date:  1997-10       Impact factor: 31.745

5.  CD8(+) T cell-mediated spontaneous diabetes in neonatal mice.

Authors:  D J Morgan; R Liblau; B Scott; S Fleck; H O McDevitt; N Sarvetnick; D Lo; L A Sherman
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

6.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

Authors:  H Nishimura; M Nose; H Hiai; N Minato; T Honjo
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

7.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

Authors:  Fumiya Hirano; Katsumi Kaneko; Hideto Tamura; Haidong Dong; Shengdian Wang; Masao Ichikawa; Cecilia Rietz; Dallas B Flies; Julie S Lau; Gefeng Zhu; Koji Tamada; Lieping Chen
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

8.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

9.  Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells.

Authors:  C Kurts; H Kosaka; F R Carbone; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

10.  CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells.

Authors:  A J Adler; D W Marsh; G S Yochum; J L Guzzo; A Nigam; W G Nelson; D M Pardoll
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

View more
  106 in total

1.  B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

Authors:  Jang-June Park; Ryusuke Omiya; Yumiko Matsumura; Yukimi Sakoda; Atsuo Kuramasu; Mathew M Augustine; Sheng Yao; Fumihiko Tsushima; Hidehiko Narazaki; Sudarshan Anand; Yingjia Liu; Scott E Strome; Lieping Chen; Koji Tamada
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

Review 2.  Inhibitors of the PD-1 Pathway in Tumor Therapy.

Authors:  Martin W LaFleur; Yuki Muroyama; Charles G Drake; Arlene H Sharpe
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

Authors:  Paul E Zarek; Ching-Tai Huang; Eric R Lutz; Jeanne Kowalski; Maureen R Horton; Joel Linden; Charles G Drake; Jonathan D Powell
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

4.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.

Authors:  Takeshi Azuma; Sheng Yao; Gefeng Zhu; Andrew S Flies; Sarah J Flies; Lieping Chen
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

5.  High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection.

Authors:  Alleluiah Rutebemberwa; Stuart C Ray; Jacquie Astemborski; Jordana Levine; Lin Liu; Kimberly A Dowd; Shalyn Clute; Changyu Wang; Alan Korman; Alessandro Sette; John Sidney; Drew M Pardoll; Andrea L Cox
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

6.  PD-1 on dendritic cells impedes innate immunity against bacterial infection.

Authors:  Sheng Yao; Shengdian Wang; Yuwen Zhu; Liqun Luo; Gefeng Zhu; Sarah Flies; Haiying Xu; William Ruff; Megan Broadwater; In-Hak Choi; Koji Tamada; Lieping Chen
Journal:  Blood       Date:  2009-04-01       Impact factor: 22.113

Review 7.  Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.

Authors:  Charles G Drake; Evan J Lipson; Julie R Brahmer
Journal:  Nat Rev Clin Oncol       Date:  2013-11-19       Impact factor: 66.675

8.  Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection.

Authors:  Beth McNally; Fang Ye; Meredith Willette; Emilio Flaño
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

9.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

Review 10.  Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

Authors:  M Segovia; S Russo; M R Girotti; G A Rabinovich; M Hill
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.